PerkinElmer Stock Forecast, Price & News

-0.96 (-0.51 %)
(As of 09/16/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume11,049 shs
Average Volume869,122 shs
Market Capitalization$20.84 billion
P/E Ratio17.69
Dividend Yield0.15%
30 days | 90 days | 365 days | Advanced Chart
Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PerkinElmer logo

About PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.38 out of 5 stars

Computer And Technology Sector

183rd out of 857 stocks

Analytical Instruments Industry

3rd out of 30 stocks

Analyst Opinion: 1.4Community Rank: 4.4Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

PerkinElmer (NYSE:PKI) Frequently Asked Questions

Is PerkinElmer a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PerkinElmer stock.
View analyst ratings for PerkinElmer
or view top-rated stocks.

What stocks does MarketBeat like better than PerkinElmer?

Wall Street analysts have given PerkinElmer a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PerkinElmer wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PerkinElmer?

PerkinElmer saw a drop in short interest during the month of July. As of July 30th, there was short interest totaling 3,630,000 shares, a drop of 19.5% from the July 15th total of 4,510,000 shares. Based on an average daily volume of 769,900 shares, the days-to-cover ratio is presently 4.7 days. Currently, 3.3% of the shares of the stock are sold short.
View PerkinElmer's Short Interest

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for PerkinElmer

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings results on Sunday, July, 25th. The medical research company reported $2.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.40 by $0.43. The medical research company had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.12 billion. PerkinElmer had a trailing twelve-month return on equity of 37.29% and a net margin of 24.35%. During the same period in the prior year, the firm posted $1.23 EPS.
View PerkinElmer's earnings history

How has PerkinElmer's stock price been impacted by Coronavirus (COVID-19)?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PKI stock has increased by 154.0% and is now trading at $185.03.
View which stocks have been most impacted by COVID-19

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Friday, July 23rd. Investors of record on Friday, October 22nd will be given a dividend of $0.07 per share on Friday, November 12th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.15%. The ex-dividend date is Thursday, October 21st.
View PerkinElmer's dividend history

Is PerkinElmer a good dividend stock?

PerkinElmer pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.15%. The dividend payout ratio of PerkinElmer is 3.37%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PerkinElmer will have a dividend payout ratio of 4.62% next year. This indicates that PerkinElmer will be able to sustain or increase its dividend.
View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its FY 2021 earnings guidance on Monday, August, 2nd. The company provided earnings per share guidance of $9.880-$9.880 for the period, compared to the Thomson Reuters consensus estimate of $9.320. The company issued revenue guidance of $4.57 billion-$4.57 billion, compared to the consensus revenue estimate of $4.41 billion.

What price target have analysts set for PKI?

8 Wall Street analysts have issued 12 month price targets for PerkinElmer's stock. Their forecasts range from $49.00 to $193.00. On average, they anticipate PerkinElmer's stock price to reach $152.77 in the next twelve months. This suggests that the stock has a possible downside of 17.4%.
View analysts' price targets for PerkinElmer
or view top-rated stocks among Wall Street analysts.

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Prahlad Ramadhar Singh, President, CEO, COO & Director
  • James M. Mock, Chief Financial Officer & Senior Vice President
  • Andrew Okun, Chief Accounting Officer & Vice President
  • Bryan A. Kipp, VP & General Manager-Life Sciences Integration
  • Joel S. Goldberg, Secretary, SVP-Administration & General Counsel

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer CEO Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among PerkinElmer's employees.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), The Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.28%), Price T Rowe Associates Inc. MD (6.72%), BlackRock Inc. (6.68%), State Street Corp (3.96%), Massachusetts Financial Services Co. MA (3.92%) and Geode Capital Management LLC (1.76%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Pascale Witz, Peter Barrett, Prahlad R Singh and Sylvie Gregoire.
View institutional ownership trends for PerkinElmer

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., FMR LLC, BlackRock Inc., Prudential PLC, Bank of America Corp DE, Bank of America Corp DE, AQR Capital Management LLC, and King Luther Capital Management Corp. Company insiders that have sold PerkinElmer company stock in the last year include Andrew Okun, Daniel R Tereau, James M Mock, Prahlad R Singh, and Sylvie Gregoire.
View insider buying and selling activity for PerkinElmer
or view top insider-selling stocks.

Which major investors are buying PerkinElmer stock?

PKI stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Amundi, Ceredex Value Advisors LLC, State of Michigan Retirement System, Goldman Sachs Group Inc., Balyasny Asset Management LLC, Glenmede Trust Co. NA, and Allianz Asset Management GmbH.
View insider buying and selling activity for PerkinElmer
or or view top insider-buying stocks.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $185.03.

How much money does PerkinElmer make?

PerkinElmer has a market capitalization of $20.74 billion and generates $3.78 billion in revenue each year. The medical research company earns $727.89 million in net income (profit) each year or $8.30 on an earnings per share basis.

How many employees does PerkinElmer have?

PerkinElmer employs 14,000 workers across the globe.

Does PerkinElmer have any subsidiaries?

The following companies are subsidiares of PerkinElmer: Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Longrun Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, Bioo Scientific Corporation, Biosense Picolabs Inc., Biosense Technologies Pvt Ltd., Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Chromo G.A. SAS, CisBio US Inc., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio Group SAS, Cisbio KK, Cisbio.com, DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, EUROIMMUN (Hangzhou) Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN (South East Asia) Pte Ltd., EUROIMMUN (Tianjin) Medical Diagnostic Technology Co. Ltd., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnóstica Ltda., EUROIMMUN Diagnostics España S.L.U., EUROIMMUN France SAS, EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics (China) Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Laboratory Diagnostics South Africa (Pty) Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Spólka z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.S., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Discovery, Immunodiagnostic Systems, Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, ManCell SAS, Nexcelom Bioscience, NovaScreen Biosciences Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Immunotec, Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin Elmer de Mexico S.A., Perkin-Elmer Argentina S.R.L., Perkin-Elmer Instruments (Philippines) Corporation, PerkinElmer (Hong Kong) Ltd., PerkinElmer (India) Pvt Ltd., PerkinElmer (Ireland) Ltd., PerkinElmer (Schweiz) AG, PerkinElmer (Shanghai) Equity Investment Fund L.P., PerkinElmer (Shanghai) Equity Investment Fund Management Co. Ltd., PerkinElmer (UK) Holdings Ltd., PerkinElmer Analytical Solutions B.V., PerkinElmer Automotive Research Inc., PerkinElmer BVBA, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.à r.l., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences (Australia) Pty. Ltd., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics (Shanghai) Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Pty. Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer Informatics Inc., PerkinElmer Instruments (Suzhou) Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS (Germany) GmbH, PerkinElmer LAS (UK) Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management (Shanghai) Co. Ltd., PerkinElmer Nederland B.V., PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Shared Services Sp z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa (Pty) Ltd., PerkinElmer Sverige AB, PerkinElmer Sweden Health Sciences Holdings AB, PerkinElmer Taiwan Corporation, PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments (Beijing) Co. Ltd., Perten Instruments AB, Perten Instruments France SASU, Perten Instruments GmbH, Perten Instruments Italia S.r.l., Perten Instruments of Australia Pty Ltd., RHS Ltd, RayAl Ltd., Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Solus Scientific Solutions Inc., Solus Scientific Solutions Ltd., Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.

When was PerkinElmer founded?

PerkinElmer was founded in 1937.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

Where are PerkinElmer's headquarters?

PerkinElmer is headquartered at 940 WINTER STREET, WALTHAM MA, 02451.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at (781) 663-6900 or via email at [email protected]

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.